The outlook is starting to look bright for biotech stocks, according to some.
With markets now expecting the first rate cut to be in September rather than June or July, as previously thought, biotech stocks could start to do well.
Biotech encompasses many different areas, but Citi has identified one with a $2.9 billion market — which it says is set for even more growth.
It gave CSL a price target of $305, or nearly 11% potential upside.
It gave Intellia a price target of $31, or 49% potential upside.
Persons:
Morgan Stanley, Garadacimab, Ionis, Citi
Organizations:
Biotech, Citi, Ionis Pharmaceuticals, Intellia Therapeutics, CSL, Intellia